A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: Trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV)

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 97-105

  Kizu, Ryoichi ^a   Nakanishi, Takeo ^a   Hayakawa, Kazuichi ^a   Matsuzawa, Akio ^b   Eriguchi, Masazumi ^b   Takeda, Yasutaka ^b   Akiyama, Nachio ^b   Tashiro, Tazuko ^c   Kidani, Yoshinori ^d,e  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NAGOYA CITY UNIVERSITY   (Japan)

^e NONE   (Japan)

Author keywords

Antitumor platinum complex; Orally active agent; Oxaliplatin derivative

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; BIS(N VALERATO)CHLORO(1,2 CYCLOHEXANEDIAMINE)(OXALATO)PLATINUM IV; BUTYRIC ACID DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HEXANOIC ACID DERIVATIVE; PLATINUM DERIVATIVE; SATRAPLATIN; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CARBOXYLATION; COMPLEX FORMATION; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; INTESTINE ABSORPTION; LEUKEMIA; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; LYMPHOMA, LARGE-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; ORGANOPLATINUM COMPOUNDS; PRODRUGS;

EID: 0032929344     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050869     Document Type: Article

References (32)

1. Alberts DS (1096) Carboplatin versus cisplatin in the chemotherapy of solid tumors. In: Pinedo HM, Schornagel JM (eds) Platinum and other metal coordination compounds in cancer chemotherapy 2. Plenum Press, New York, pp 303-309
2. Ayres GH, Meyers AS Jr (1951) Spectrophotometric study of the platinum(IV)-tin(II) chloride system. Anal Chem 23: 299-304
3. Burchenal JH, Kalaher K, Dew K, Lokys L (1979) Rationale for the development of platinum analogs. Cancer Treat Rep 63: 1493-1498
4. Burchenal JH, Irani G, Kern K, Lokys L, Turkevich J (1980) 1,2-diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 74: 146-155
5. Chaney SG, Wyrick SD, Till GK (1990) In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res 50: 4539-4545
6. Christian MC (1992) The current status or new platinum analogs. Semin Oncol 19: 720-733
7. Clear MJ, Hydes PC, Hepburn DR, Malerbi BW (1980) Antitumor platinum complexes: structurc-activity relationship. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: current status and new developments. Academic Press, New York, pp 149-170
8. Giandomenico CM, Abram MJ, Murrer BA, Vollano JF, Barnard CFJ, Harrap KR, Goddard PM, Kelland LR, Morgan SE (1991) Synthesis and reactions of a new class of orally active Pt(IV) antitumor complexes. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York. pp 93-100
9. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol Hematol 15: 191-219
10. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53: 2581-2586
11. Kidani Y, Inagaki K, Saito, R, Tsukagoshi S (1977) Synthesis and anti -tumor activities of platinum(II) complexes of 1,2-diaminocyclohexane isomers and their related derivatives. J Clin Hematol Oncol 7: 197-209
12. Kidani Y, Noji M, Tashiro T (1980) Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Jpn J Cancer Res 71: 637-643
13. Kizu R, Higashi S, Kidani Y, Miyazaki, M (1993) Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31: 475-480
14. Kizu R, Nakanishi T, Miyazaki M, Tashiro T, Noji. M, Matsuzawa A, Eriguchi M, Takeda Y, Akiyama N, Kidani Y (1996) An orally active antitumor cyclohexanediamine-Pt(IV) complex: trans,cis,cis-bis(n-valerato)(oxalato)(1R,2R-cyclohexanediamine)Pt(IV). Anti-Cancer Drugs 7: 248-256
15. Kizu R, Nakanishi T, Yamamoto S, Hayakawa K, Matsuzawa A, Eriguchi M, Takeda Y, Akiyama N, Kidani Y (1998) Significance of water solubility in the gastrointestinal absorption of trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)-platinum(IV), an orally active antitumor platinum complex, and its analogues. Anti-cancer Drugs 9: 167-174
16. Loehrer PJ, Einhorn LH (1984) Cisplatin, diagnosis and treatment. Ann Intern Med 100: 704-713
17. Mathé G, Kidani Y, Noji M, Maral R, Bourut C, Chenu E (1985) Antitumor activity of 1-OHP in mice. Cancer Lett 2: 135-143
18. Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Musset JL (1986) A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (I-OHP). Biomed Pharmacother 40: 372-376
19. Mathé G, Kidani Y, Sekiguchi M, Eriguchi M, Gredj G. Peytavin G, Misset HL, Brienza S, De Vassals F, Chenu E, Bourut C (1989) Oxalato-platinum or 1-OHP, a third generation platinum complex: and experimental and clinical appraisal and preliminary comparison with cis-platin and carboplatin. Biomed Pharmacother 43: 237-250
20. Mauldin SK, Gibbons G, Wyrick SD, Chancy SG (1988) Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 48: 5136-5144
21. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer BA, Santabarbara P, Harrap KR, Judson IR (1995) Phase I and pharmacological study of an oral platinum complex (JM216): dose dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451-458
22. Noji M, Sumi M, Ohmori T, Mizuno M, Suzuki K, Tashiro T, Kidani Y (1988) Antitumor activity and property of platinum(IV) complexes containing 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers (in Japanese). Nihon Kagaku Kaishi 675-683
23. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970-5976
24. Raynaud FI, McKeage MJ, Ward J, Berry C, Odell D, Murrer BA, Santabarbara P, Judson IR, Harrap KR (1995) Pharmacokinetic study of orally administered ammine diacetato dichloro (cyclohexylamine) platinum (IV) (JM216) in a 5-day dose schedule phase I clinical trial. In: Zeller WJ, D'Indalci M, Newell DR (eds) Novel approaches in anticancer drug design. Molecular modelling and new treatment strategies. Karger, Basel, pp 100-108
25. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52: 1855-1865
26. Rose WC (1986) Evaluation of platinol analogs using the M5076 murine sarcoma. Anticancer Res 6: 557-562
27. Rose WC (1997) Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 40: 51-56
28. Rose WC, Crosswell AR, Schurig JE, Casazza AM (1993) Preclinical antitumor activity of orally administered platinum(IV) complexes. Cancer Chemother Pharmacol 32: 197-203
29. Soulié P, Raymond E, Misset JL, Cviktovic E (1996) Oxaliplatin: update on an active and safe dach platinum complex. In: Pinedo HM, Schornagel JH (eds) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, pp 165-174
30. Tashiro T (1988) Development of new antitumor platinum complexes (in Japanese). Nihon Kagaku Kaishi 1988: 684-690
31. Tashiro T, Kawada Y, Sakurai Y, Kidani Y (1989) Antitumor activity of a new platinum complex, oxalato(trans-1-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 43: 251-260
32. Yarbo JW (1992) Carboplatin (JM8) update: current perspectives and future directions. Semin Oncol 19: 72-77